Venomtech Ltd

As a complementary service to our T-VDA venom libraries, we can manage projects in house for you and produce data reports. This service can be an add on to any of our T-VDA products (including custom venom libraries) and go through Hit, confirmation, ID and even SAR and lead development.

Many publications identify proteins and peptides from venoms as useful positive controls for particular assays, such as Psalmotoxin for ASIC channels, ProToxII for NaV1.7 channel etc. Using our expertise in venom fractionation, we can isolate and characterise specific proteins. Pricing depends on species yield, purification strategy and amount needed. Please contact us with your specific needs.

With the huge array of drug discovery, cosmetic and crop science targets out there, it is not uncommon for our customers to need ligands and tools for targets which have not yet been prosecuted. We offer a custom array design service, using our expertise in combination with databases and published literature to produce T-VDAs for novel targets. Many of these custom arrays perform so well that they later become standard T-VDAs.

This custom service has lead us into novel venom pharmacology such as interactions with epigenetic targets including S100 and bromodomains, but also glutamate transporters and others.

Where possible, we will source new species to add to our collection, often at no additional cost to our customers. We can even include customer’s own preferred species, provided that they can be obtained in a way that is compliant with the Nagoya protocol. See the Biodiversity Information page on our website for further information.

Unlock the full potential of our Targeted Venom Discovery Arrays™ (T-VDAs) with this custom hit characterisation and lead optimisation service. The Venomtech team have decades of experience in global pharmaceutical drug discovery, coupled with specialist knowledge of venoms and venomous animals. Using our industry-leading proprietary safe working practices we turn millions of years of evolution into the ultimate drug discovery pipeline. This starts with the T-VDA already optimised to provide biological tools in areas where synthetic chemistry has failed or where a biological is specifically sought.

1.Full identification of active component(s)

• Characterisation of active fraction(s)
  
  • LC-MS, MALDI-TOF, MS/MS
    
• Purification of single active(s)
  
  • For libraries not fully pre-fractionated
    
• Resupply of actives for dose response testing
  
  • Milligram quantities purified from original venoms
    
• Small scale synthesis of the pure active
  
  • Up to grams, either synthetic (<150 amino acids) or cloned for larger proteins
    
• Large (up to 1kg) synthetic production (<150 amino acids) of single peptides, at GMP grade if needed.
  

2.Hit-to-lead development

• Provision of closely related targeted venoms to enhance potency and/or selectivity
  
• Determination of structure-activity relationship (SAR)
  
• Modifications for improved stability, delivery, bioavailability, etc
  
• Toxicity testing, proof of concept and proof of mechanism in standard models